TY  - GEN
AU  - Soria,J-C
AU  - Fülöp,A
AU  - Maciel,C
AU  - Fischer,J R
AU  - Girotto,G
AU  - Lago,S
AU  - Smit,E
AU  - Ostoros,G
AU  - Eberhardt,W E E
AU  - Lishkovska,P
AU  - Lovick,S
AU  - Mariani,G
AU  - McKeown,A
AU  - Kilgour,E
AU  - Smith,P
AU  - Bowen,K
AU  - Kohlmann,A
AU  - Carlile,D J
AU  - Jänne,P A
TI  - SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer
SN  - 1569-8041
PY  - 2018///0502
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Benzimidazoles
KW  - administration & dosage
KW  - Carcinoma, Non-Small-Cell Lung
KW  - drug therapy
KW  - Disease-Free Survival
KW  - Docetaxel
KW  - Double-Blind Method
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Proto-Oncogene Proteins p21(ras)
KW  - genetics
KW  - Taxoids
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
UR  - https://doi.org/10.1093/annonc/mdx628
ER  -